不同种族群体中贝塞斯达细胞病理学分类与手术病理学的比较。

Comparison of Bethesda cytopathology classification to surgical pathology across racial-ethnic groups.

作者信息

Bresler Amishav, Mehta Vikas, Schiff Bradley A, Smith Richard V, Khader Samer, Ramos-Rivera Gloria, Lin Juan, Libutti Steven K, Laird Amanda M, Ow Thomas J

机构信息

Department of Otorhinolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey.

Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York.

出版信息

Head Neck. 2019 Jul;41(7):2340-2345. doi: 10.1002/hed.25707. Epub 2019 Feb 21.

DOI:10.1002/hed.25707

PMID:30793405

Abstract

BACKGROUND

The Bethesda System standardized the reporting of thyroid cytopathology and created categories to provide an estimation of a nodule's risk of malignancy. There are limited data describing their utility in different racial-ethnic groups.

METHODS

A retrospective chart review of thyroid fine-needle aspirations (FNA) was performed within our health-care systems. Sensitivity, specificity, positive predictive value (PPV), and negative predictive values (NPVs) were calculated for the total cohort, and racial-ethnic groups.

RESULTS

The sensitivity, specificity, PPV, and NPV of the entire cohort was 93%, 77%, 57%, and 97%. Among patients who underwent surgery, African Americans contained a high number of Bethesda II FNAs (63%) compared to Hispanics (48%) and whites (45%). The sensitivity, specificity, and NPV were comparable among groups, the PPV was lowest for African Americans (43%), followed by Hispanics (60%) and whites (69%).

CONCLUSIONS

The Bethesda system's predictive value may differ among racial-ethnic groups.

摘要

背景

贝塞斯达系统规范了甲状腺细胞病理学报告，并创建了分类以评估结节的恶性风险。描述其在不同种族-族裔群体中效用的数据有限。

方法

在我们的医疗保健系统内对甲状腺细针穿刺活检（FNA）进行回顾性病历审查。计算了整个队列以及种族-族裔群体的敏感性、特异性、阳性预测值（PPV）和阴性预测值（NPV）。

结果

整个队列的敏感性、特异性、PPV和NPV分别为93%、77%、57%和97%。在接受手术的患者中，非裔美国人的贝塞斯达II类FNA数量较多（63%），相比之下西班牙裔为48%，白人为45%。各群体之间的敏感性、特异性和NPV相当，非裔美国人的PPV最低（43%），其次是西班牙裔（60%）和白人（69%）。